Ficlatuzumab

Phase 3Monoclonal antibody

AAVEO Pharmaceuticals, Inc.

Ficlatuzumab is one of 142 biologic programs targeting Pancreatic Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

141

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Squamous Cell CarcinomaActive, not recruiting

Pancreatic CancerPhase 1

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 3

Active, not recruiting

Acute Myeloid LeukemiaPhase 1/Phase 2

Active, not recruiting

Squamous Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Ficlatuzumab

AAVEO Pharmaceuticals, Inc.

Phase 3

1 2

Gemzar

GGynecologic Oncology Group

MS Contin

1 4

Medrol

Pfizer

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

ABI-007

Bristol-Myers Squibb

Preclinical

2 7

Active Comparator

Moderna

Preclinical

1 8

LDE225

Novartis

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

Thiazolidinediones

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Head and Neck Squamous Cell Carcinoma

NCT06064877

Q4 2028

Phase 1/2Recruiting

Acute Myeloid Leukemia

NCT03013998

Clinical

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma3 trials

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Recruiting·AAVEO Pharmaceuticals, Inc.·Phase 3·NCT06064877·410 enrolled

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

Terminated·—·Phase 1·NCT02277184·1 enrolled

Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Completed·JJames J Lee·Phase 1·NCT02277197·14 enrolled

Acute Myeloid Leukemia2 trials

A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Withdrawn·AAVEO Pharmaceuticals, Inc.·Phase 2·NCT04100330

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Recruiting·BBeat AML, LLC·Phase 1/2·NCT03013998·3,000 enrolled

Pancreatic Cancer1 trial

Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

Completed·—·Phase 1·NCT03316599·26 enrolled

ESS1 trial

Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

No longer available·AAVEO Pharmaceuticals, Inc.··NCT02090127

Metastatic1 trial

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label

Terminated·AAVEO Pharmaceuticals, Inc.·Phase 2·NCT02318368·10 enrolled

2 more indications

Refractory AML1 trial

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

Terminated·CC. Babis Andreadis·Phase 1·NCT02109627·17 enrolled

Squamous Cell Carcinoma1 trial

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

Completed·UUniversity of Arizona·Phase 2·NCT03422536·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Ficlatuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ficlatuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ficlatuzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AVEO Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: AAVEO Pharmaceuticals, Inc.

Ficlatuzumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2028

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma3 trials

Acute Myeloid Leukemia2 trials

Pancreatic Cancer1 trial

ESS1 trial

Metastatic1 trial

Refractory AML1 trial

Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News